Oxcarbazepine (All indications)

Urinary malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12831
R48324		 Thomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Urinary malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.70 [0.04;11.46] C
excluded (control group) 		1/71   1/50 2 71
ref
S12833
R48336		 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Urinary malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 0.80 [0.09;6.71] C 1/71   6/340 7 71
ref
S9074
R31066		 Tomson (Oxcarbazepine), 2018 Renal malformations at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.44 [0.03;7.70] C 0/333   8/2,514 8 333
ref
S9057
R30919		 Artama (Oxcarbazepine), 2005 Urinary system 1st trimester retrospective cohort (registry) unexposed, sick Adjustment: No 3.17 [0.13;78.41] C 0/99   1/939 1 99
ref
Total 3 studies 0.92 [0.20;4.14] 16 503
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021Thomas, 2021 1 0.80[0.09; 6.71]77150%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Tomson (Oxcarbazepine), 2018Tomson, 2018 2 0.44[0.03; 7.70]833328%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Artama (Oxcarbazepine), 2005Artama, 2005 3 3.17[0.13; 78.41]19922%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 0.92[0.20; 4.14]165030.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine; 3: Oxcarbazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.92[0.20; 4.14]165030%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Tomson (Oxcarbazepine), 2018 Artama (Oxcarbazepine), 2005 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.22[0.21; 7.18]81700%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Artama (Oxcarbazepine), 2005 2 exposed to other treatment, sickexposed to other treatment, sick 0.44[0.03; 7.70]8333 -NATomson (Oxcarbazepine), 2018 1 Tags Adjustment   - No  - No 0.92[0.20; 4.14]165030%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Tomson (Oxcarbazepine), 2018 Artama (Oxcarbazepine), 2005 3 All studiesAll studies 0.92[0.20; 4.14]165030%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Tomson (Oxcarbazepine), 2018 Artama (Oxcarbazepine), 2005 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12831

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.22[0.21; 7.18]81700%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Artama (Oxcarbazepine), 2005 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.56[0.08; 4.12]104040%NAThomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Oxcarbazepine), 2018 20.510.01.0